ClinicalTrials.gg
RecruitingNCT07700758Updated Nov 10, 2026

A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

A Phase 2 interventional study of Belzutifan in Malignant Neoplasm, sponsored by Merck Sharp & Dohme LLC. Recruiting at 10 sites in 7 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingFirst sites in 7 new countries+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Study summary

Researchers are looking for new ways to treat adolescents with locally advanced, unresectable, or metastatic solid tumors. Participants were enrolled into pheochromocytoma/paraganglioma (PPGL), wild type gastrointestinal stromal tumor (wtGIST), and Von Hippel-Lindau (VHL) disease-associated localized tumors cohorts:

  • PPGL are rare cancers that start in cells that make hormones in the adrenal glands
  • wtGIST is a less common type of cancer that starts in the digestive tract. Wild type means it does not have certain gene mutations (changes)
  • VHL disease-associated localized tumors are rare tumors caused by a certain gene mutation that may be passed down from parents to children
  • Locally advanced means the cancer has spread into nearby tissue
  • Unresectable means the cancer cannot be removed by surgery
  • Metastatic means the cancer has spread to other parts of the body

The goal of the study is to learn about the safety of belzutifan and if people tolerate it.

02

Conditions studied

  • Malignant Neoplasm

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's planned enrollment of 15 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a diagnosis of one of the following: locally advanced, unresectable, or pheochromocytoma/paraganglioma or wild-type gastrointestinal stromal tumors, or localized tumors associated with von Hippel-Lindau disease
  • Has per 1.1

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a pulse oximeter reading \<92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
  • Has cardiac disease or indicating uncontrolled cardiac condition or has congenital long syndrome
  • Has a history of infection
  • Has received prior treatment with any hypoxia inducible factor-2α inhibitor, including belzutifan
  • Has had an allogenic tissue/solid organ transplant
  • Has a history of stem cell transplant within 6 months of start of study intervention
  • Has known additional that is progressing or has required active treatment within the past 2 years
  • Has known active central nervous system and/or carcinomatous meningitis
  • Has an active infection requiring systemic therapy
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Belzutifan

    Participants will receive belzutifan 80 mg (body weight \<40 kg) or 120 mg (body weight ≥40 kg) orally once daily for approximately 2 years.

    Drug: Belzutifan

Interventions

  • Administered once daily via oral tablet

    Also known as: MK-6482, PT2977, WELIREG®

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants that experience AEs will be reported.

    Time frame: Up to approximately 5 years

  2. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants that discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to 24 hours of Belzutifan

    Blood samples will be collected at specified intervals to determine the area under the concentration-time curve from time 0 to 24 hours of belzutifan.

    Time frame: At designated timepoints (up to 5 weeks)

  2. Minimum Plasma Concentration (Cmin) of Belzutifan

    Blood samples will be collected at specified intervals to determine the Cmin of belzutifan.

    Time frame: At designated timepoints (up to 5 weeks)

  3. Maximum Plasma Concentration (Cmax) of Belzutifan

    Blood samples will be collected at specified intervals to determine the Cmax of belzutifan.

    Time frame: At designated timepoints (up to 5 weeks)

  4. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by investigator will be reported.

    Time frame: Up to approximately 5 years

  5. Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by investigator will be reported.

    Time frame: Up to approximately 5 years

07

Study locations

10 of 10 sites recruiting
  • University of Iowa ( Site 5017)
    Iowa City, Iowa 52242, United States
    Recruiting
    • Study Coordinator · Contact319-356-2296
  • UZ Gent ( Site 5428)
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
    • Study Coordinator · Contact+32 9 332 16 53
  • Rigshospitalet ( Site 5467)
    Copenhagen, Capital Region 2100, Denmark
    Recruiting
    • Study Coordinator · Contact+4535455002
  • Centre Hospitalier Universitaire de Nantes - Hopital Mere Enfant ( Site 5104)
    Nantes, Loire-Atlantique 44093, France
    Recruiting
    • Study Coordinator · Contact+33240087805
  • Seoul National University Hospital-Pediatrics ( Site 5972)
    Seoul, 03080, South Korea
    Recruiting
    • Study Coordinator · Contact+82-2-2072-1673
  • Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 5973)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact82-10-8708-4286
  • Hospital Sant Joan de Déu-Pediatric Oncology Department ( Site 5717)
    Esplugas de Llobregat, Barcelona 08950, Spain
    Recruiting
    • Study Coordinator · Contact+34671600093
  • Hospital Universitari Vall d Hebron ( Site 5716)
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact+34934893093
  • Hospital Infantil Universitario Nino Jesus ( Site 5715)
    Madrid, 28009, Spain
    Recruiting
    • Study Coordinator · Contact+34915035900 ext 662
  • National Taiwan University Hospital ( Site 5983)
    Taipei, 100225, Taiwan
    Recruiting
    • Study Coordinator · Contact8862-23123456#70559
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jan 2034, 86 months after the start.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 86 months is above that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 14, 2026
StartActual
Oct 13, 2026was Nov 2026
Primary completionEst.
Jan 2, 2034
CompletionEst.
Jan 2, 2034
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
10 sites added — first sites in United States, South Korea, Belgium, Spain, France and 2 more
All 7 countries

United States, South Korea, Belgium, Spain, France, Taiwan, Denmark

Show 10 added (3 Spain, 2 South Korea, 1 United States, 1 Belgium, 1 France, 1 Taiwan, 1 Denmark)
  • University of Iowa ( Site 5017) · Iowa City, United States
  • Seoul National University Hospital-Pediatrics ( Site 5972) · Seoul, South Korea
  • UZ Gent ( Site 5428) · Ghent, Belgium
  • Hospital Infantil Universitario Nino Jesus ( Site 5715) · Madrid, Spain
  • Centre Hospitalier Universitaire de Nantes - Hopital Mere Enfant ( Site 5104) · Nantes, France
  • Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 5973) · Seoul, South Korea
  • National Taiwan University Hospital ( Site 5983) · Taipei, Taiwan
  • Rigshospitalet ( Site 5467) · Copenhagen, Denmark
  • Hospital Sant Joan de Déu-Pediatric Oncology Department ( Site 5717) · Esplugas de Llobregat, Spain
  • Hospital Universitari Vall d Hebron ( Site 5716) · Barcelona, Spain
across 5 updates, Oct 5, 2026 – Nov 10, 2026
Start date
Nov 23, 2026→Oct 13, 2026 (actual)
Oct 23, 2026
Contact
Study contact's phone or email changed: T•••@msd.com→T•••@merck.com. See the current contact
Oct 5, 2026
Show all 6 updates
  1. Nov 10, 2026
    3 sites added — first site in Denmark
    Show 3 added (2 Spain, 1 Denmark)
    • Rigshospitalet ( Site 5467) · Copenhagen, Denmark
    • Hospital Sant Joan de Déu-Pediatric Oncology Department ( Site 5717) · Esplugas de Llobregat, Spain
    • Hospital Universitari Vall d Hebron ( Site 5716) · Barcelona, Spain
    + 1 other change: verification date
  2. Oct 30, 2026
    3 sites added — first sites in France and Taiwan
    Show 3 added (1 France, 1 South Korea, 1 Taiwan)
    • Centre Hospitalier Universitaire de Nantes - Hopital Mere Enfant ( Site 5104) · Nantes, France
    • Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 5973) · Seoul, South Korea
    • National Taiwan University Hospital ( Site 5983) · Taipei, Taiwan
    + 1 other change: references
  3. Oct 23, 2026
    Start date Nov 23, 2026→Oct 13, 2026 (now actual)
  4. Oct 21, 2026
    2 sites added — first sites in Belgium and Spain
    Show 2 added (1 Belgium, 1 Spain)
    • UZ Gent ( Site 5428) · Ghent, Belgium
    • Hospital Infantil Universitario Nino Jesus ( Site 5715) · Madrid, Spain
  5. Oct 19, 2026
    1 site added — first site in South Korea
    Show site
    • Seoul National University Hospital-Pediatrics ( Site 5972) · Seoul, South Korea
  6. Oct 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • University of Iowa ( Site 5017) · Iowa City, United States
    Contact Study contact's phone or email changed: T•••@msd.com→T•••@merck.com. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07700758
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Oct 13, 2026
Primary completion
Jan 2, 2034 (estimated)
Completion
Jan 2, 2034 (estimated)
Last update
Nov 10, 2026

Study contacts

Toll Free Number
Contact
Trialsites@merck.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belzutifan

Start the discussion